CL2021003280A1 - Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal - Google Patents
Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renalInfo
- Publication number
- CL2021003280A1 CL2021003280A1 CL2021003280A CL2021003280A CL2021003280A1 CL 2021003280 A1 CL2021003280 A1 CL 2021003280A1 CL 2021003280 A CL2021003280 A CL 2021003280A CL 2021003280 A CL2021003280 A CL 2021003280A CL 2021003280 A1 CL2021003280 A1 CL 2021003280A1
- Authority
- CL
- Chile
- Prior art keywords
- renal failure
- fabry disease
- patients
- methods
- patient
- Prior art date
Links
- 208000024720 Fabry Disease Diseases 0.000 title abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 title abstract 2
- 201000006370 kidney failure Diseases 0.000 title abstract 2
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 abstract 2
- 229950007469 migalastat Drugs 0.000 abstract 2
- GRGNVOCPFLXGDQ-TWHXEDJUSA-N (2r,3r,4s,5r,6r)-2-[(2r,3r,4r,5r,6s)-6-[(2r,3s,4r,5r,6r)-6-[(e,2s,3r)-2-amino-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](N)[C@H](O)/C=C/CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 GRGNVOCPFLXGDQ-TWHXEDJUSA-N 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859904P | 2019-06-11 | 2019-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003280A1 true CL2021003280A1 (es) | 2022-10-07 |
Family
ID=71950725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003280A CL2021003280A1 (es) | 2019-06-11 | 2021-12-09 | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220313670A1 (https=) |
| EP (1) | EP3982962A1 (https=) |
| JP (2) | JP7677910B2 (https=) |
| KR (1) | KR20220019796A (https=) |
| CN (1) | CN114423427A (https=) |
| AR (1) | AR120055A1 (https=) |
| AU (2) | AU2020291002A1 (https=) |
| BR (1) | BR112021024886A2 (https=) |
| CA (1) | CA3141226A1 (https=) |
| CL (1) | CL2021003280A1 (https=) |
| EA (1) | EA202290024A1 (https=) |
| IL (1) | IL288677A (https=) |
| MX (1) | MX2021015352A (https=) |
| PH (1) | PH12021553102A1 (https=) |
| TW (1) | TW202112372A (https=) |
| WO (1) | WO2020252129A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2573498T3 (es) | 2006-05-16 | 2016-06-08 | Amicus Therapeutics, Inc. | Opciones de tratamiento para la enfermedad de Fabry |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| CA3224537C (en) | 2017-05-30 | 2025-09-09 | Amicus Therapeutics, Inc. | USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE |
| CA3090496C (en) | 2018-02-06 | 2024-03-26 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| EP4282472A3 (en) | 2018-08-20 | 2024-02-21 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| EP3851105B1 (en) | 2019-08-07 | 2026-03-04 | Amicus Therapeutics, Inc. | Migalastat for use in treating fabry disease in patients having a mutation in the gla gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| AU2008232614A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| EP2150254A4 (en) * | 2007-04-26 | 2010-11-10 | Amicus Therapeutics Inc | DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| CN103974619B (zh) * | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| AR109103A1 (es) * | 2016-07-19 | 2018-10-31 | Amicus Therapeutics Inc | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert |
| EP3565583A4 (en) * | 2017-01-05 | 2020-12-02 | Protalix Ltd. | TREATMENT DIET FOR THE TREATMENT OF FABRY'S DISEASE USING STABILIZED ALPHA-GALACTOSIDASE |
| PT4324522T (pt) * | 2017-05-30 | 2026-03-13 | Amicus Therapeutics Inc | Métodos de tratamento de pacientes com fabry tendo insuficiência renal |
| AR111971A1 (es) * | 2017-05-30 | 2019-09-04 | Amicus Therapeutics Inc | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
| CA3224537C (en) * | 2017-05-30 | 2025-09-09 | Amicus Therapeutics, Inc. | USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE |
-
2020
- 2020-06-11 AR ARP200101648A patent/AR120055A1/es unknown
- 2020-06-11 WO PCT/US2020/037174 patent/WO2020252129A1/en not_active Ceased
- 2020-06-11 EP EP20751716.0A patent/EP3982962A1/en active Pending
- 2020-06-11 CN CN202080042938.3A patent/CN114423427A/zh active Pending
- 2020-06-11 US US17/618,277 patent/US20220313670A1/en active Pending
- 2020-06-11 JP JP2021573404A patent/JP7677910B2/ja active Active
- 2020-06-11 KR KR1020227000878A patent/KR20220019796A/ko active Pending
- 2020-06-11 EA EA202290024A patent/EA202290024A1/ru unknown
- 2020-06-11 CA CA3141226A patent/CA3141226A1/en active Pending
- 2020-06-11 TW TW109119640A patent/TW202112372A/zh unknown
- 2020-06-11 BR BR112021024886A patent/BR112021024886A2/pt unknown
- 2020-06-11 MX MX2021015352A patent/MX2021015352A/es unknown
- 2020-06-11 AU AU2020291002A patent/AU2020291002A1/en not_active Abandoned
- 2020-06-11 PH PH1/2021/553102A patent/PH12021553102A1/en unknown
-
2021
- 2021-12-05 IL IL288677A patent/IL288677A/en unknown
- 2021-12-09 CL CL2021003280A patent/CL2021003280A1/es unknown
-
2025
- 2025-05-01 JP JP2025076158A patent/JP2025131572A/ja active Pending
-
2026
- 2026-01-29 AU AU2026200618A patent/AU2026200618A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202290024A1 (ru) | 2022-03-14 |
| KR20220019796A (ko) | 2022-02-17 |
| EP3982962A1 (en) | 2022-04-20 |
| JP7677910B2 (ja) | 2025-05-15 |
| CN114423427A (zh) | 2022-04-29 |
| AU2020291002A1 (en) | 2022-01-06 |
| CA3141226A1 (en) | 2020-12-17 |
| BR112021024886A2 (pt) | 2022-01-25 |
| AU2026200618A1 (en) | 2026-04-16 |
| US20220313670A1 (en) | 2022-10-06 |
| JP2025131572A (ja) | 2025-09-09 |
| PH12021553102A1 (en) | 2023-10-09 |
| AR120055A1 (es) | 2022-02-02 |
| IL288677A (en) | 2022-02-01 |
| TW202112372A (zh) | 2021-04-01 |
| JP2022536687A (ja) | 2022-08-18 |
| MX2021015352A (es) | 2022-04-06 |
| WO2020252129A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003280A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| MX2022004137A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| MX2018007669A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| CO2022002638A2 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| MX2023005628A (es) | Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry. | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| MX2018002816A (es) | Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. | |
| MX2022003610A (es) | Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| AR117861A1 (es) | Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry | |
| AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal | |
| EP4324522A3 (en) | Methods of treating fabry patients having renal impairment | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| EA201992869A1 (ru) | Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность | |
| GEAP202416526A (en) | Treatment of major depressive disorder | |
| UA109966C2 (uk) | Спосіб лікування латентної ішемічної хвороби серця у хворих на бронхіальну астму | |
| AR122298A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen una mutación en el gen gla |